Spire Wealth Management’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Spire Wealth Management’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.17M	Buy	+52,257	New	+$2.1M	0.07%	253

Other funds holding FTXH

Nilsine Partners Greenwood Village, Colorado $1.44B AUM 38.08% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

NewSquare Capital Newtown Square, Pennsylvania $1.38B AUM 24% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return

Daymark Wealth Partners Cincinnati, Ohio $4.41B AUM 22.52% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return

Cyndeo Wealth Partners St. Petersburg, Florida $2.21B AUM 17.29% 1-Year Est. Return

Spire Wealth Management's FTXH Position: Q3 2026 in Review

Spire Wealth Management opened a new position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q3 2026: 52,257 shares worth $2.17M. The stake represents 0.07% of the portfolio and ranks #253 among its holdings.

33 funds tracked by Wall St. Rank hold FTXH as of Q3 2026.

Spire Wealth Management held 52,257 shares of First Trust Nasdaq Pharmaceuticals ETF worth $2.17M as of Q3 2026.
First Trust Nasdaq Pharmaceuticals ETF was a new Spire Wealth Management position in Q3 2026.
First Trust Nasdaq Pharmaceuticals ETF made up 0.07% of Spire Wealth Management's portfolio in Q3 2026, its #253 holding.
33 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q3 2026.

Based on Spire Wealth Management's 13F filing for Q3 2026, filed 30 Oct 2026.